Trevi Therapeutics
TRVI
13.35
-0.37
-2.70%
Trevi Therapeutics
US · TRVI
#2810 by market cap
Listed 2019
13.35
-0.37
-2.70%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
About Trevi Therapeutics
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.
- Founded
- 2011
- CEO
- Ms. Jennifer L. Good
- Employees
- 34
- Headquarters
- New Haven, Connecticut, United States of America
- Fiscal year end
- 12-31
- Website
- trevitherapeutics.com
Company profile
- Exchange
- US
- Symbol
- TRVI
- Market-cap rank
- #2810
- Listing date
- 2019-05-07
- Market cap
- 1.90B
- Float cap
- 1.59B
- Shares out
- 142.56M
- Float shares
- 118.81M
Sectors & themes
Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.
Trevi Therapeutics discussion 0 comments